Targeted therapies for urothelial carcinoma: From FGFR inhibitors to next‑generation antibody-drug conjugates (Review)
International Journal of Oncology · 2025
DOI: 10.3892/ijo.2025.5841 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Oncology, 2025. Verfasst von Jinping Du und 4 weiteren Autor:innen. Beteiligte Einrichtung: Gansu University of Chinese Medicine, Lanzhou, Gansu 730000, P.R. China. Hauptthemen laut MEDLINE: Immunoconjugates, Protein Kinase Inhibitors, Molecular Targeted Therapy, Receptors, Fibroblast Growth Factor. Die Arbeit nennt 130 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gansu University of Chinese Medicine, Lanzhou, Gansu 730000, P.R. China.
Zitieren
APA
Du, J., Shen, H., Zeng, T., Liu, W., & Xie, Y. (2025). Targeted therapies for urothelial carcinoma: From FGFR inhibitors to next‑generation antibody-drug conjugates (Review). International Journal of Oncology. https://doi.org/10.3892/ijo.2025.5841
Vancouver
Du J, Shen H, Zeng T, Liu W, Xie Y. Targeted therapies for urothelial carcinoma: From FGFR inhibitors to next‑generation antibody-drug conjugates (Review). International Journal of Oncology. 2025. doi:10.3892/ijo.2025.5841
BibTeX
@article{Du2025,
author = {Du, Jinping and Shen, Hao and Zeng, Tongwei and Liu, Wei and Xie, Yongqiang},
title = {Targeted therapies for urothelial carcinoma: From FGFR inhibitors to next‑generation antibody-drug conjugates (Review)},
journal = {International Journal of Oncology},
year = {2025},
doi = {10.3892/ijo.2025.5841}
}
EUVIMED